TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07016633: A Phase Ib/IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 Consecutive Multiple Treatment for 12 Weeks in Adult Patients With MASH

Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,030,400

Rescue Site Savings

+$5,954,420

Unlock Full NCT07016633 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07016633 Rescue Dossier →